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 Cancers arise from epigenetic and genetic alteration.  Rate- limiting 
accumulation of such alterations combined with natural selection 
leads to complex changes in cell behavior that underlie cancer 
development and progression ( 1 , 2 ). Although the number of genetic 
alterations involved in driving cancer development is probably 
larger than originally expected, many alterations found in tumors 
may not contribute to cancer formation, but merely be passenger 
or bystander alterations occurring serendipitously, or as a neutral 
consequence of genomic and proteomic deregulation. Distinguishing 
whether alterations drive cancer development or arise as passengers 
is critical for our understanding of the cellular processes leading 
to cancers as well as for the design of intervening strategies. 
 Tripartite motif family protein 27 (TRIM27) was previously 
identiﬁ ed as a gene involved in oncogenic rearrangements with the 
RET tyrosine kinase receptor ( 3 , 4 ). More recently, evidence has 
emerged that the non-rearranged allele is highly and/or ectopically 
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 Background  The tripartite motif family protein 27 (TRIM27) is a transcriptional repressor that interacts with, and attenuates 
senescence induction by, the retinoblastoma-associated protein (RB1). High expression of TRIM27 was noted 
in several human cancer types including breast and endometrial cancer, where elevated TRIM27 expression 
predicts poor prognosis. Here, we investigated the role of TRIM27 expression in cancer development. 
  Methods  We assessed TRIM27 expression in human cancer using cancer profiling arrays containing paired tumor and 
normal cRNA (n = 261) as well as in murine skin cancer induced by 7, 12-dimethylbenzanthracene (DMBA)/12-O-
tetradecanoylphorbol-13-acetate (TPA). We generated mice with disrupted expression of murine TRIM27 
(Trim27   /   ) and assessed their susceptibility to DMBA/TPA-induced skin tumor development compared 
with isogenic littermates (n = 26 mice per group). We assessed the effect of Trim27 loss on senescence propen-
sity in mouse embryonic fibroblasts (MEFs) by quantifying cell proliferation alongside senescence markers 
(senescence-associated   -galactosidase [SA-  -gal] activity and hypertrophic cell morphology). The contribution 
of RB1 on senescence and cancer susceptibility (n > 20 mice per group) in Trim27   /   backgrounds was also 
assessed. Data were analyzed using the Student’s  t ,   2 , or log-rank test as indicated. All statistical tests were 
two-sided. 
  Results  TRIM27 transcript levels are statistically significantly increased in common human cancers, including colon and 
lung, vs normal tissues (TRIM27 expression relative to ubiquitin: cancers vs normal tissues, mean = 0.59, 95% con-
fidence interval [CI] = 0.55 to 0.63 vs mean = 0.46, 95% CI =0.43 to 0.49,  P < .001) as well as in chemically induced 
mouse skin cancer compared with matched normal tissue (Trim27 expression relative to Gapdh control: tumor vs 
normal skin, mean = 4.2, 95% CI = 3.97 to 4.43 vs mean = 0.96, 95% CI = 0.69 to 1.2,  P < .001). Trim27   /   mice 
(n = 14) were resistant to chemically induced skin cancer development (eight [57.2%] of 14 mice were tumor free) 
compared with Trim27   /   wild-type littermates (n = 13) (one [7.7%] of 13 mice was tumor free). Trim27   /   MEFs 
show enhanced senescence propensity in response to replicative (percentage of SA-  -gal-positive cells: Trim27   /   
MEFs vs Trim27   /   MEFs, mean = 14.2%, 95% CI = 11.1% to 17.4% vs mean = 53.3%, 95% CI = 48.7% to 57.9%, 
 P < .001) or oncogenic stress (percentage of SA-  -gal-positive cells: Trim27   /   MEFs + Ras vs Trim27   /   MEFs + Ras, 
mean = 24.0%, 95% CI = 19.9% to 28.1% vs mean = 37.3%, 95% CI = 32.2% to 42.4%,  P < .05) compared with 
Trim27   /   MEFs. These responses were alleviated following inactivation of murine RB1 (Rb1). Furthermore, Trim27   /   
mice are not protected from cancers arising as a consequence of Rb1 deletion (median survival: Trim27   /   Rb   /   
vs Trim27   /   Rb   /   , 14 vs 13 months; difference = 1.0 month, 95% CI = 0.5 to 1.6 months,  P = .14). 
  Conclusion  TRIM27 expression is a modifier of disease incidence and progression relevant to the development of common 
human cancers and is a potential target for intervention in cancer. 
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expressed in speciﬁ c cancer types, including seminomas, breast, 
and endometrial cancers ( 5 – 7 ). In endometrial cancers , TRIM27 
positivity predicted unfavorable clinical outcome ( 6 ). Such evidence 
is consistent with a linkage of TRIM27 expression to the natural 
history of cancer and indicates a role for the gene and its encoded 
product in cancer development. 
 The TRIM27 protein belongs to an extended, yet poorly 
understood , family of proteins that feature as a common denomi-
nator a tripartite combinatorial motif encompassing RING ﬁ nger, 
B-box, and coiled-coil domain homologies ( 8 ). Various members 
of this gene family are implicated in ubiquitin metabolic processes , 
and several have been linked to pathology of diseases, including 
cancer ( 9 – 12 ). 
 Current functional information indicates  that  TRIM27 is asso-
ciated with a variety of subcellular topologies and processes. 
Several interactions of TRIM27 with other proteins have been 
reported including with the E3 SUMO protein ligase PIAS3 
( 13 , 14 ), several ubiquitin-conjugating enzymes ( 15 – 17 ), chromatin 
components such as enhancer of polycomb ( 18 ) and the EID-1 
inhibitor of differentiation and protein acetylation ( 19 ), as well as 
several members of the inhibitor of nuclear factor kappa B kinases 
(IKKs) ( 20 ). We recently described that TRIM27 can inhibit acti-
vation of gene transcription by the product of the retinoblastoma 
susceptibility gene  ( RB1 ) and that its ectopic expression restrains 
senescence expressivity arising in cells with chronic RB1 product 
activity ( 19 ). Our previous data suggested that TRIM27 acts to 
modify the function of the RB1 tumor suppressor in cells. Here , 
we investigated the role of TRIM27 in cancer development using 
the two-stage chemical carcinogenesis in mouse skin ( 21 ). 
 Materials and Methods 
 Cancer  Expression  Profiling 
 A commercial  cancer- profiling array (Clontech, BD Biosciences, 
Oxford, UK) with paired normal and micro-dissected cancer 
 tissue – derived cRNA preparations was sequentially hybridized 
with radiolabeled cDNA representing TRIM27-  or ubiquitin as per 
the  manufacturer ’ s  instructions. Hybridization signals were detected 
by phosphoimaging using a Storm 820 System for data collection 
and ImageQuant software (GE Healthcare, Buckinghamshire, 
UK) linked to Microsoft Office Excel (version 2007, licensed to 
University College London, London, UK) for analysis. 
 Generation of Trim27  Mutant  Mice 
 XP0484 embryonic stem cells containing a gene trap insertion into 
exon 1 of the mouse Trim27 locus were obtained from Sanger 
Institute Gene Trap Resource ( www . sanger . ac . uk / PostGenomics / 
genetrap / protocols . shtml ). The site of insertion was mapped by 
Expand Long Template PCR System (Roche, West Sussex, UK) 
using Trim27 intron 1 spanning primers (forward  5 ′ -
GGGAGCCTCTGAAGCTGTACT- 3 ′ , reverse  5 ′ -TCTTTCA
CTCTTCTTAG- 3 ′ ). Chimeric mice were produced and back-
crossed to syngeneity (n > 8, where n is equal to the number of 
generations) into C57BL6 backgrounds. Mouse experiments were 
done in accordance with protocols approved by the Institutional 
Review Board on animal experiments at the Institute of Cancer 
Research (London, UK) in line with the UK Animals (Scientific 
Procedures) Act of 1986. Genotyping of mice was performed using 
the following primers: F1:  5 ′ -ACAAAGGAGATGCACATG
GAGC- 3 ′ ; R2:  5 -GCCAGCAAGTGTGTTAGCAA- 3 ′ ;  and 
R3:  5 ′ -GCTTCACTGAGTCTCTGGCAT- 3 ′ . 
 Cell  Culture ,  Proliferation , and  Senescence 
 Primary mouse embryonic fibroblasts (MEFs) were derived from 
individual day 13.5 embryos obtained from Trim27   /    ×  Trim27   /   
crosses as previously described ( 22 ). Briefly, heads and red organs 
were removed , and the embryo torso  was  minced using a sterile 
scalpel. Tissue clumps were dispersed by treatment with 0.5% 
trypsin (Sigma, Dorset, UK) for 30  minutes at 37°C. The resulting 
cells suspension was mixed with  Dulbecco’s  modified Eagle 
medium (Gibco, Paisley, UK) supplemented with 10% fetal bovine 
serum (PAA Labs, Somerset, UK) and seeded into two 25-cm 2 
flasks per embryo. Cells were subcultured when confluent into a 
10-cm diameter dish and incubated for 2 days. These cells were 
frozen in aliquots and considered passage 0 (P0). Cells were main-
tained in an incubator with 5% CO 2 at 37°C, 3% O 2 . Analysis of a 
minimum of three independent MEF pairs was undertaken for 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Tripartite motif family protein 27 (TRIM27) has previously been 
implicated as having a potential role in cancer development. The 
mechanisms by which TRIM27 participates in cancer development 
are poorly understood, although previous data suggest that 
TRIM27 modifies the function of the retinoblastoma-associated 
protein (RB1) tumor suppressor in cells. 
 Study design 
 To investigate the role of TRIM27 in the development of cancer, 
mice with defective expression of the TRIM27 murine ortholog 
(Trim27) were generated. The skin of Trim27   /   and Trim27   /   
wild-type mice was exposed to 7, 12-dimethylbenzanthracene 
(DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA), as part of a 
two-step carcinogenesis model, and tumor incidence was com-
pared. In vitro studies with Trim27   /   and Trim27   /   mouse embry-
onic fibroblasts investigated senescence in response to replicative 
and oncogenic stress. The role of TRIM27 in cancers caused by the 
loss of murine RB1 (Rb1) was also studied using Trim27/Rb1 genet-
ically engineered mice. 
 Contribution 
 Tumor incidence in response to carcinogen exposure among 
Trim27   /   mice was decreased compared with Trim27   /   wild-type 
littermates. Increased senescence was observed when Trim27   /   
MEFs were exposed to replicative or oncogenic stress. The inci-
dence of cancers driven by Rb1 loss was not altered. 
 Implication 
 Trim27 plays a role in tumor development in mice and is a poten-
tial chemopreventative and therapeutic target for humans. 
 Limitation 
 A murine skin cancer model was used vs a murine model of human 
cancers in which TRIM27 is overexpressed, and should be used in 
future studies. 
 From the Editors 
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each dataset. Short-term MEF proliferation was measured by 
plating equal cell numbers (9  ×  10 4 cells) from each genotype into 
six-well plates in triplicate. Trypsin – EDTA solution (1 mL of a 
0.25% solution) (Sigma) was added to cell cultures, cells were col-
lected, and then counted using a Scepter (PHCC20060) cell 
counter (Merck-Millipore, Watford, UK). 
 MEFs were cultured by the schedule set out in the 3T3 culti-
vation protocol. The protocol was carried out as previously 
described ( 23 ). Brieﬂ y, 3  ×  10 5 MEF cells were plated in 25-cm 2 
ﬂ asks for each genotype. After  3  days , the total number of cells in 
the ﬂ ask was counted and 3  ×  10 5 cells were replated for 28 – 30 
passages. The fold cell growth was calculated by dividing the 
number of cells counted at each passage by the number of cells 
initially plated (ie , 3  ×  10 5 cells). For the study of replicative senes-
cence, cells were maintained in 5% CO 2 at 37°C with ambient O 2 . 
Senescence-associated   -galactosidase  (SA-  -gal)  was assayed as 
previously described ( 24 ). Brieﬂ y, MEFs (1  ×  10 4 cells) in six-well 
dishes were ﬁ xed in 0.5% glutaraldehyde (in  phosphate-buffered 
saline [ PBS ] ) (Sigma) for 15 min utes at room temperature and 
washed in PBS supplemented with 1 mM MgCl 2 . MEFs were 
stained with X-gal solution (1 mg/mL X-gal [Sigma], 5 mM 
K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 1 mM MgCl 2 in PBS at pH 6.0) 
overnight at 37°C and SA-  -gal positive cells quantiﬁ ed by scoring 
2 – 3 eye ﬁ elds (between 100 – 200 cells) per well. 
 DNA  Constructs  and  Retroviral  Infection 
 Oncogenic Ras (HRas V12) was transduced using a pBabe- puro-
 based vector (pBABE puro HRas V12) (Addgene plasmid 9051 ; 
 Addgene, Cambridge, MA) or a murine stem cell  virus – based 
vector with integral internal ribosome entry site linked to the 
enhanced form of green fluorescent protein (MSCV/HRas V12/
RES/GFP) (Addgene plasmid 18780). pBABE-puro (Addgene 
plasmid 1764) or parent MSCV/IRES/GFP (Addgene plasmid 
9044) were used as controls. pBabe-puro-HPV16E7 expressing 
human papilloma virus 16 early protein E7 was provided by Dr 
Karl Muenger (Harvard Medical School, Boston, MA). The gener-
ation of retroviruses and infection of cells followed standard proce-
dures. Briefly, the retroviral vector DNA was transfected into 
BOSC23 or Phoenix ( RVC-10001;  Orbigen, San Diego,  CA ) pack-
aging cells (1  ×  10 6 cells) using Fugene HD (Roche) or calcium 
 phosphate (Promega, Southampton, UK) , using the  manufactur-
er’s  instruction. Cells were maintained in  Dulbecco’s  modified 
Eagle medium (Gibco) supplemented with 10% fetal bovine serum 
(PAA Labs) in an incubator with 5% CO 2 at 37°C. Retrovirus con-
taining supernatants were harvested 48 and 72  hours after transfec-
tion, pooled, filtered through a 0. 45- μ M membrane , and mixed 
with polybrene (Sigma) to yield a final concentration of 4%. Viral 
preparations were stored at   80°C or used to infect MEFs at pas-
sage 2 – 4. 
 For retroviral infections , MEFs were plated at 1  ×  10 6 cells per 
 10- cm dish 24 hours before infection. For infection, the culture 
medium was replaced by polybrene-containing viral supernatant , 
and MEFs were incubated at 37°C for 8  hours at which time 
a second aliquot of virus was added for a further 8 hours. After 
16 hours, infected cell populations were subjected to selection for 
virus uptake. Cells were cultured in the presence of 2  μ g/mL 
puromycin (Sigma) for vectors encoding puromycin resistance or 
subjected to ﬂ uorescent cell sorting for vectors encoding green 
ﬂ uorescent protein (GFP). 
 Quantitative  Real - Time  Polymerase  Chain  Reaction 
 RNA expression levels were determined by quantitative real-time 
polymerase chain reaction (qRT-PCR) using an ABI Prism 7700 
Sequence Detection System (Applied Biosystems, Paisley, UK). 
Total cellular RNA was isolated with TRIzol (Invitrogen, Paisley, 
UK) using the  manufacturer’s  protocol. Total RNA (1  μ g) was 
reverse  transcribed into cDNA using Superscript II RNase H 
Reverse Transcriptase kit (Invitrogen). Fluorogenic Taqman 
probes and TaqMan One-step RT-PCR master reagent were used 
for the qRT-PCR. Four Taqman mouse primer sets (catalog 
numbers Mm01136022, Mm00493339, Mm00493340, and 
Mm00493341; Applied Biosystems) were used to amplify Trim27. 
 The GAPDH detection kit from Applied Biosystems was used to 
amplify glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
The qRT-PCR product values obtained for Trim27 were normal-
ized using those obtained for GAPDH for the respective samples. 
 In  Vivo  Tumor  Experiments 
 For the two-stage skin tumorigenesis, the dorsal skin of age-
matched ( 8- week-old) female and male mice, generated from 
crossing Trim27   /   male and female mice in a C57BL6/DBA 
F1 genetic background, was shaved. The following day , 150  μ L 
of 125  μ g/mL 7, 12 - dimethylbenzanthracene  (DMBA) (Sigma) 
was topically applied to the shaved area to initiate tumor develop-
ment. One week following initiation, 150  μ L of 10   4 M 12-O-
tetradecanoylphorbol-13-acetate (TPA) (Sigma) was topically 
applied to the same area. Application was repeated twice weekly for 
the duration of the experiment, up to a maximum of 20 weeks. 
Mice were killed by CO 2 asphyxiation if any individual tumor 
became ulcerated or reached a diameter of 1.5 cm, if mice showed 
signs of distress, or at the experiment endpoint. Tumors were 
excised at the experiment endpoint along with tumor-adjacent and 
remote normal tissue as required for the experiments. Specimens 
were quick-frozen in liquid nitrogen for RNA and DNA analysis 
and either fresh frozen in Optimal Cutting Temperature (OCT) 
solution (Raymond Lamb, Surrey, UK) or fixed in 4%  paraformal-
dehyde (Sigma) and paraffin embedded for histology assessments. 
Histopathology was performed for tumors from Trim27   /   (n = 13) 
and Trim27   /+ (n = 17) mice at week 22 after the initiation. Sections 
of tumors embedded into paraffin were stained using hematoxylin 
and eosin (Sigma). For Keratin 14 immunohistochemistry, antigen 
retrieval was performed in 10 mM citrate buffer pH 6.0 for 
15  minutes in a microwave at 90°C followed by a  20- minute cool-
down period at room temperature.  Specimens were stained using 
rabbit polyclonal Keratin 14 antibody (dilution: 1/1000, PRB-155P ; 
 Covance, Leeds, UK) followed by horseradish peroxidase – coupled 
secondary antibody following standard procedures. The  researcher 
who examined and scored the specimen was blinded to the genotype 
and the type of treatment administered to the mice. 
 For the generation of Trim27   /   Rb1   /   mice, C57BL6 mice 
with disruption of the Rb1 locus through insertion of two iterative 
in-frame stop codons in exon  3  of the Rb1 gene ( 25 ) were paired 
with C57BL6 mice carrying the XP0484 Trim27 gene disruption. 
Genotyping was performed using genomic DNA from an ear-clip 
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biopsy with duplex PCR with primers Rbx3 ( 5 ′ -AATTGCGGC
CGCATCTGCATCTTTATCGC- 3 ′ ) and RI3 ( 5 ′ -CCCATGTT
CGGTCCCTAG- 3 ′ ) for the Rb1  wild- type allele, and primers 
Rbx3 and PGK3 ’ ( 5 ′ -GAAGAACGAGATCAGCAG- 3 ′ ) for the Rb1 
disrupted allele. Trim27   /   Rb   /+ , Trim27   /+ Rb   /+ , Trim27   /   Rb   /   , 
and Trim27   /+ Rb   /   mice were observed during a period of 
20 months for the appearance of thyroid and/or pituitary tumors. 
Mice that showed signs of distress or deterioration were killed 
under  schedule  1 of the UK Animals (Scientiﬁ c Procedures) Act of 
1986. The pituitary gland and thyroid were examined for abnor-
malities along with all other internal organs. Surviving mice were 
killed at 20 months and examined. The  researcher who examined 
the mice and recorded tumor incidence was blinded to the geno-
type of the mice. All in vivo experiments were approved by the 
UK Home Ofﬁ ce and performed following  the  United Kingdom 
Coordinating Committee on Cancer Research Guidelines for the 
welfare and use of animals in cancer research. 
 Histochemical  Detection  of   -Geo and SA-  - Galactosidase 
 Activity 
 Fresh  whole- mount skin or tumors and sections of skin or tumors 
recently fresh frozen into OCT were fixed in 1% paraformalde-
hyde, 0.2% glutaraldehyde in PBS containing 2  mM magnesium 
chloride, 5  mM EGTA , and 0.02% Nonidet P-40 (NP-40) for 2 
hours or 20  minutes, respectively, followed by three 30-minute 
rinses in PBS and 0.02% NP-40. For   -Geo detection, specimen 
were incubated in 5-bromo-4-chloro-indolyl-  -D-galactopyrano-
side (X-gal) solution (1 mg/mL X-gal, 5  mM potassium ferrocya-
nide, 5 mM potassium ferricyanide, 2 mM magnesium chloride, 
0.01% sodium deoxycholate, and 0.02% NP-40 in PBS, pH 7.3) 
for 4 hours at 37°C. SA-  -gal was assayed essentially as described 
earlier. After the development of stain, samples were rinsed three 
times for 30 minutes each with PBS, 0.02% NP-40, mounted 
in 4’,6-diamidino-2-phenylindole (DAPI ) – containing mounting 
medium, and examined microscopically for evidence of staining. 
 Protein  Analysis  and  Antibodies 
 Cell lysates were prepared in radio-immunoprecipitation assay 
buffer (PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl sulfate , and protease inhibitor cocktail ; Roche). Protein 
samples were separated by sodium dodecyl sulfate – polyacrylamide gel 
electrophoresis (SDS-PAGE)  and  then transferred to polyvinyli-
dene difluoride membrane of 0.45- μ m pore size (GE Healthcare). 
Membranes were blocked with 5% nonfat dry milk in Tris-buffered 
saline (TBS; 25 mM Tris, 150 mM NaCl, 2 mM KCl, pH 7.4) with 
0.1% Tween-20 (Sigma-Aldrich, Dorset, UK), referred to as 
TBST, at room temperature for 2 hours, followed by incubation at 
4°C overnight with primary antibodies. Antibody used were rabbit 
polyclonal anti-p19 Arf (dilution: 1/1000, ab80 ;  Abcam, Cambridge, 
UK), mouse polyclonal anti-pan-Ras (dilution: 1/1000 ;  Calbiochem, 
London, UK), mouse monoclonal anti-p21 (dilution: 1/1000, F5 ; 
 Santa Cruz Biotechnology , Santa Cruz , CA ), mouse monoclonal 
anti-  -actin (dilution: 1/1000, ACTN05 ;  NeoMarkers, Surrey, 
UK), mouse monoclonal anti-p53 (dilution: 1/1000, 1C12 ;  Cell 
Signaling, Hertfordshire, UK). Membranes were washed three 
times, 15 minutes each, with TBST before incubation at room 
temperature for 45 minutes with peroxidase-conjugated secondary 
antibodies (Dako UK Ltd, Cambridgeshire, UK) at 1:5000 dilu-
tion. All antibody dilutions were done in TBST with 1% nonfat 
dry milk. After washing the membranes with TBST three times, 15 
minutes each, bound antibodies were visualized using Western 
Blotting Luminal Reagent (Santa Cruz Biotechnology). 
 Statistical  Analysis 
 Data were analyzed using   2 , Student’s  t , or  log -rank test as appro-
priate for the analysis. Student’s  t test variants were applied as 
appropriate and are indicated, paired tests were used when pos-
sible, and heteroscedastic tests were applied when the samples 
compared showed unequal variance. Results were considered sta-
tistically significant when  P was less than .05. Means and 95% 
confidence intervals are calculated where appropriate. Statistical 
analyses were performed using Office Excel (version 2007, 
Microsoft Office ;  licensed to University College London, 
London, UK) or GraphPad Prism (version 5 ;  GraphPad Software 
Inc, La Jolla , CA ). All statistical tests were two-sided. Experiments 
were powered to permit detection of 20% alteration in tumor 
incidence with 99% certainty at  P = .05. Power calculations used 
 the  Cohen  d . 
 Results 
 TRIM27  Expression  in  Human  and  Mouse  Cancers 
 Previous studies have shown an increase in TRIM27 expression in 
specific cancers ( 5 – 7 , 26 ). We investigated whether enhanced 
TRIM27 expression may be detectable in other types of cancer and 
how widely this may be seen across cancer subtypes. We probed a 
commercial cancer-profiling array containing tumor cRNA (n = 
261) alongside cRNA from paired normal tissue (n = 261) using the 
TRIM27-  coding region. Ubiquitin was used to control for 
loading-related signal inequalities. Analysis of normalized data 
across all samples revealed statistically significantly increased mean 
expression of TRIM27 in cancers vs normal tissues (TRIM27 
expression relative to ubiquitin: cancers vs normal, mean = 0.59, 
95% CI = 0.55 to 0.63 vs mean = 0.46, 95% CI =  0.43 to 0.49,  P < 
.001) ( Figure 1, A and  Supplementary  Figure  1 ,  A , available 
online). TRIM27 expression was increased between two- and five-
fold in individual cancers across all histological types, with others 
showing equal or decreased expression compared with matched 
normal tissue controls ( Supplementary  Figure  1 ,  B – C , available 
online). Separation of data by tumor type indicates statistically 
significant increased TRIM27 expression in uterine (TRIM27 
expression relative to ubiquitin: uterine cancers vs normal uterine 
tissues, mean = 0.74, 95% CI = 0.63 to 0.85 vs mean = 0.50, 95% 
CI = 0.44 to 0.56,  P < .001, n = 42), colon (TRIM27 expression 
relative to ubiquitin: colon cancers vs normal colon tissues, 
mean = 0.50, 95% CI = 0.43 to 0.57 vs mean = 0.38, 95% CI = 0.30 
to 0.46,  P < .01, n = 35), rectal (TRIM27 expression relative to 
ubiquitin: rectal cancers vs normal rectal tissues, mean = 0.76, 95% 
CI = 0.51 to 1.0 vs mean = 0.43, 95% CI = 0.35 to 0.51,  P < .01, 
n = 18), and lung (TRIM27 expression relative to ubiquitin: lung 
cancers vs normal lung tissues, mean = 0.61, 95% CI = 0.47 to 0.75 
vs mean = 0.41, 95% CI = 0.35 to 0.47,  P < .01, n = 21) cancers 
( Figure 1, B and  Supplementary  Figure  1 ,  D , available online). 
Although TRIM27 expression was not statistically significantly 
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altered in breast cancer tissue, a subset of breast cancers showed 
enhanced expression when compared with paired normal tissue 
( Supplementary  Figure  1 ,  D , available online), potentially reflect-
ing selective overexpression of TRIM27 in specific subgroups of 
disease, as was suggested in a recently published report ( 7 ). 
 To determine if Trim27 expression was increased in murine 
cancers , we examined murine tumors induced by exposure of the 
skin to the carcinogen DMBA followed by TPA treatment ( 27 , 28 ). 
Isolated tumor foci derived from individual mice 32 weeks after 
initiation were compared with paired samples of normal mouse 
skin using qRT-PCR. A statistically signiﬁ cant increase in Trim27 
expression was observed among the murine cancers vs murine 
normal skin (Trim27 expression relative to Gapdh control: tumor 
vs normal skin, mean = 4.2, 95% CI = 3.97 to 4.43 vs mean = 0.96, 
95% CI = 0.69 to 1.2,  P < .001) ( Figure 1, C ), and was comparable 
to the degree by which Trim27 transcript levels were altered in the 
human cancer samples tested. 
 We further examined Trim27 expression in tumors and skin of 
mice at different stages of tumor development and compared expres-
sion between tumor foci that had developed in individual mice, 
which classically present with multifocal disease ( 21 ) ( Figure 1, D 
and E ). This revealed statistically signiﬁ cantly higher expression in 
tumors compared with normal skin at 13 weeks, which is a time 
when lesions are known to be hyperplastic and clonal yet mostly 
diploid ( 21 ) (Trim27 expression relative to Gapdh control: tumor 
vs normal skin, mean = 51.6, 95% CI = 34.2 to 69.0 vs mean = 1.34, 
95% CI = 0.88 to 1.8,  P < .001). Also, at 20 weeks, when anaplasia 
develops and lesions become progressively aneuploid ( 21 ), tumors 
again had statistically higher expression of Trim27 compared with 
normal skin (Trim27expression relative to Gapdh control: tumor 
vs normal skin, mean = 15.9, 95% CI = 11.4 to 20.4 vs mean = 1.34, 
95% CI = 0.88 to 1.8,  P < .001) ( 21 ). Levels of expression were 
remarkably high, 20- to 40-fold above normal skin, in early 
( 13- week) lesions, as opposed to 10- to 20-fold in late ( 20- week) 
lesions. Furthermore , tumors without overt increase of Trim27 
expression are found at both late and early times. 
 In contrast to the above, untreated and treated skin harvested 
 2  weeks following carcinogen exposure, a time at which tumors 
had not yet formed, showed comparable Trim27 expression. 
Likewise, when remotely located normal skin and tumor-adjacent 
skin harvested early (13 weeks) or late (20 weeks) following tumor 
initiation was compared, Trim27 expression was similar. Together , 
these results indicate that increased Trim27 expression accom-
panies and is exaggerated during early cancer development. 
 Furthermore, and paralleling the human data, inter-tumor 
heterogeneity exists in these murine cancers and is detectable 
at early (13 weeks) as well as late (20 weeks) times during cancer 
development, indicating that such heterogeneity more likely 
reﬂ ects the nature of the initiating event than cancer evolution 
during progression. Collectively, the data indicate increased 
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 Figure 1 .  The tripartite motif family protein 27 ( TRIM27 ) expression in 
human and mouse cancer.  A and  B ) TRIM27 expression was assessed 
using Clontech  cancer- proﬁ ling arrays containing 261 paired cancer 
and normal samples. Data were normalized to expression of Ubiquitin 
(UBI).  A ) A box plot of the relative expression of TRIM27 in human 
tumors and corresponding normal tissues is shown. *** P < .001 
using heteroscedastic two-tailed Student’s  t test.  B ) Box plots depicting 
TRIM27 expression patterns for speciﬁ c cancer types are shown. 
Paired two-tailed Student’s  t test was used to compare TRIM27 expres-
sion in cancer vs normal tissues ** P < .01, *** P < .001. The number of 
tumors analyzed for each type are provided in  Supplementary  Figure 
 1 (available online).  C ) Box plot shows the expression of the Trim27 
murine  ortholog in chemically induced mouse skin tumors (n = 4) vs 
normal skin (n = 4) obtained 32 weeks after cancer initiation. 
Quantitative reverse transcription polymerase chain reaction analysis 
of Trim27 mRNA expression was done. Data were normalized to the 
expression of glyceraldehyde-3-phosphate dehydrogenase (Gapdh) 
and are presented as the relative quantitative score, with the mean 
Trim27 expression in corresponding skin set to 1. *** P < .001 using the 
paired two-tailed Student’s  t test.  D ) Trim27 transcript in  chemically 
induced mouse skin, skin tumors, and normal skin in different mice 
(mouse 1 = ms1, mouse 2 = ms2, mouse 3 = ms3) obtained at week 2, 
13, or 20 after tumor initiation. Data were normalized to the expression 
of Gapdh and are presented as the relative quantitative score, with the 
mean Trim27 expression in an arbitrarily chosen normal skin sample 
(ms3, week 2) set to 1. Mean expression levels are shown with corre-
sponding 95% conﬁ dence intervals ( error bars ). Data from three repli-
cates of one representative experiment are shown.  E ) Box plots 
showing the expression of the Trim27 murine  ortholog in chemically 
induced mouse skin, skin tumors, and normal skin at 13 or 20 weeks 
after initiation are given. Data were normalized to the expression of 
Gapdh and are presented as the relative quantitative score with the 
mean Trim27 expression in an arbitrarily chosen normal skin sample 
(continued)
set to 1. Normal skin (n = 8), tumors (n = 8) at week 13, tumors (n = 12) 
at week 20. Heteroscedastic two-tailed Student’s  t test was used to 
calculate  P . *** P < .001. The box  plots  depict the median , and 25th to 
75th percentiles with 5th to 95th percentiles are represented by the 
 whisker bars . 
Figure 1 (continued).
Downloaded from https://academic.oup.com/jnci/article-abstract/104/12/941/912518
by Library Institute of Cancer Research user
on 08 August 2018
946 Articles | JNCI Vol. 104, Issue 12  |  June 20, 20126   Article | JNCI Vol. 104, Is ue 12 | June 20, 2012
TRIM27 expression across a considerable range of cancer types, 
including cancer in the mouse, and imply a role of TRIM27 over-
expression in early cancers and cancer development. 
 Generation of  Mice  With  Disruption  of the  Murine  Trim27 
 Locus 
 To investigate if TRIM27 expression contributes to cancer devel-
opment , we generated mice using mouse embryonic stem cells 
with a gene  trap integration into the Trim27 locus. Long-range 
PCR combined with sequencing confirmed single-site integration 
into the first intron of the murine Trim27 gene ( Figure 2, A ). 
Positioning of the gene  trap, which uses an En-2 splice acceptor 
site to direct fusion of the preceding exonic sequence to a bacterial 
  -galactosidase-(lacZ)-geneticin resistance hybrid gene, disrupts 
the murine Trim27 locus within the tripartite motif domain. 
Germline-modified chimeras, generated using these  embryonic 
stem cells , gave rise to viable offspring that transmitted the trapped 
allele in a Mendelian fashion ( Figure 2, B and  Supplementary 
 Table  1 , available online), yielding normal sex ratios ( Supplementary 
 Table  1 , available online). Mice with heterozygously or homozy-
gously trapped Trim27 allele were indistinguishable from isogenic 
wild-type littermates, displaying no detectable differences in fitness, 
fertility, longevity , or behavior ( Supplementary  Table  1 , available 
online, and data not shown). 
 We used qRT-PCR to conﬁ rm that the gene trap insertion 
affected  the  production of Trim27 transcript, using an intron 
1-spanning probe set for Trim27 ( Figure 2, C ). Levels of Trim27 
transcript in 14.5-day embryos were near detection limit in Trim27   /   
embryos (Trim27 expression relative to Gapdh control, mean = 
0.0055, 95% CI = 0.0051 to 0.0059) and reduced by approximately 
50% in Trim27   /   (Trim27 expression relative to Gapdh control, 
mean = 0.53, 95% CI = 0.47 to 0.59) compared with Trim27   /+ 
wild-type littermates (Trim27 expression relative to Gapdh 
control, mean = 1.0, 95% CI = 0.93 to 1.07) ( Figure 2, D ). A com-
parable reduction in signal was also seen with probe  sets spanning 
Trim27 introns 2, 3 , or 4 ( Supplementary  Figure  2 , available 
 Figure 2 .  Gene trap – facilitated TRIM27 disrup-
tion.  A ) Schematic representation of gene  trap 
insertion into the murine Trim27 locus. Insertion 
of the trap vector into intron 1 leads to splicing 
of the intron 1 splice donor into the trap 
encoded engrailed 2 ( En2 ) intron1 splice acceptor 
(SA), generating an in-frame   -Geo fusion tran-
script followed by transcript termination. The 
locations of polymerase chain reaction (PCR) 
primers (F1, R3, R2) for distinguishing normal 
and trapped alleles are indicated.  B ) The via-
bility of mice with the homozygously trapped 
Trim27 allele was determined. Multiplex PCR 
genotyping in the offspring of heterozygously 
trapped Trim27 mice was done. Wild  type (wt) 
denotes the product from the normal, untrapped 
allele (660 bp) through priming with F1 and R2; 
mutant (mt) denotes the product from the 
trapped allele (731 bp) through priming with F1 
and R3.  C – E ) The effect of gene  trap insertion 
on Trim27 expression was determined.  C ) The 
position of primers for quantitative reverse 
transcription PCR analysis (qRT-PCR) is shown. 
 D ) Trim27 expression in 14. 5- d ay embryos by 
qRT-PCR analysis. Data were normalized to 
the expression of glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) and are presented as 
the relative quantitative score, with the mean 
Trim27 expression in wild-type embryos set to 
1. Mean expression levels and 95% conﬁ dence 
intervals ( error bars ) from three replicates of 
each representative embryo are shown.  E ) 
Trim27 expression in adult mouse organs was 
determined by qRT-PCR. Data represent the 
relative means for two individual mice normal-
ized to the Gapdh control. Results for Trim27   / 
organs were set to 1. 
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online) indicating that the gene  trap insertion blocked generation 
of wild-type Trim27 transcript effectively and that no measurable 
intron skipping occurs that could give rise to C-terminal products 
from the trapped allele. To test if loss of Trim27 transcript pro-
duction arises in adult mice , we looked at a panel of mouse organs. 
In line with prior published information ( 29 ), Trim27 transcript 
levels in adult organs were low compared with those seen in 
embryos with the exception of adult testis. In this organ (Trim27 
expression relative to Gapdh control in testis, mean = 11.8, 95% 
CI = 10.7 to 13.0) , a more than 10-fold higher expression of 
Trim27 was recorded than that seen in isogenic embryos (Trim27 
expression relative to Gapdh control in embryos, mean = 1.0, 95% 
CI = 0.86 to 1.15) ( Supplementary  Figure  3 , available online). 
Importantly, parallel analysis of organs from mice with hemizy-
gously (Trim27   /   ) or homozygously (Trim27   /   ) trapped Trim27 
revealed statistically signiﬁ cant lower levels of Trim27 transcript 
in the former and near absence in the latter across all organs tested 
( Figure 2, E ) in comparison to Trim27   /+ littermates (Trim27 
expression relative to Gapdh control, Trim 27   /   liver vs Trim27   /   
liver vs Trim27   /+ liver, mean = 0.77, 95% CI = 0.70 to 0.88 vs 
mean = 0.025, 95% CI = 0.018 to 0.033 vs mean = 1.0, 95% CI = 
0.9 to 1.16; Trim27   /   lung vs Trim27   /   lung vs Trim27   /+ lung, 
mean = 0.58, 95% CI = 0.48 to 0.7 vs mean = 0.017, 95% CI = 
0.014 to 0.022 vs mean = 1.0, 95% CI = 0.87 to 1.13; Trim27   /   
brain vs Trim27   /   brain vs Trim27   /+ brain, mean = 0.33, 95% CI = 
0.27 to 0.39 vs mean = 0.0044, 95% CI = 0.0028 to 0.0065 vs 
mean = 1.0, 95% CI = 0.85 to 1.17), consistent with observation in 
embryos. We concluded that the trap insertion robustly reduced 
the level of wild-type Trim27 transcript, giving rise to mice in 
which Trim27 is expressed at a substantially reduced level (Trim27 
hypomorphs). 
 Skin  Carcinogenesis  in  Mice  with Trim27  Disruption 
 To assess whether the reduced production of Trim27 transcript 
may affect tumor formation , we examined tumor development in 
mice following DMBA/TPA exposure of their skin. Our previous 
analysis ( Figure 1, C ) showed increased expression of Trim27 at 
high frequency in such tumors. Tumors were detected in the 
carcinogen-treated mice 9 – 10 weeks after the initial application of 
DMBA and arose with similar latency in both Trim27   /+ and 
Trim27   /   mice ( Figure 3, A ). However, a statistically significant 
percentage of Trim27   /   mice did not develop tumors. Among the 
Trim27   /   mice,  eight  (57.2 %) of 14 remained tumor  free , whereas 
only  one (7.7%)  of 13 Trim27   /+ mice  was tumor  free after 22 weeks, 
the time at which the experiment was terminated. The resistance to 
tumor development in Trim27   /   mice was also demonstrated by a 
reduced tumor burden in these mice. Trim27   /   tumor-bearing 
mice developed a smaller number of tumors compared with 
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  Figure 3 .  Skin carcinogenesis in wild-type (Trim27   / ) and Trim27 
mutant (Trim27   /   ) mice.  A – C ) Disease presentation in mice subjected 
to a two-stage chemical carcinogenesis protocol was studied , and 
statistical signiﬁ cance was measured by two-sided   2 tests. * P = .03, 
*** P < .001.  A ) Tumor incidence in Trim27   / (n = 13) and Trim27   /   
(n  = 14) mice and  B ) the average number of tumors per mouse among 
Trim27   / (n = 6) and Trim27   /   (n = 2) were determined.  C ) The tumor 
burden for Trim27   / and Trim27   /   mice (n = 13 and n = 14 respectively) 
was determined by caliper measurements of mouse skin tumors for the 
indicated times after tumor initiation.  D ) Box plot showing the expression 
of the Trim27 murine  ortholog in chemically induced mouse skin 
Trim27   /   tumors (n = 4) vs Trim27   / tumors (n = 4) obtained 32 weeks 
after tumor initiation. Quantitative reverse transcription polymerase 
chain reaction analysis of Trim27 mRNA expression was done , and the 
data were normalized to the expression of glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) and are presented as the relative quantitative 
score, with the mean Trim27 expression in Trim27   /   tumors set to 1. 
The median ( horizontal lines ), 25th to 75th percentiles ( boxes ), and 
5th to 95th percentiles ( whiskers ) are indicated. *** P < .001 using 
heteroscedastic two-tailed Student’s  t test. 
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tumor-bearing Trim27   /+ littermates (number of tumors per 
mouse: Trim27   /   vs Trim27   /+ , mean = 2.28, 95% CI = 0.57 to 
3.99 vs mean = 6.38, 95% CI = 3.78 to 8.98,  P = .03 as measured by 
the   2 test) ( Figure 3, B and C ) , with tumors remaining small at week 
22, only rarely reaching a size of 3 mm or larger (tumors >3  mm 
in diameter: Trim27   /   vs Trim27   /+ , 11.1% vs 21.3%,  P < .001, 
  2 test) ( Figure 3, C ). At week 22, tumors were processed and 
stained with hematoxylin – eosin and for keratin 14. The morphology 
and histology of Trim27   /   and Trim27   /+ tumors  were  identical. 
Evidence for stromal microinvasion was seen ;  yet these were 
detected regardless of genotype ( Supplementary  Table  2 , available 
online). 
 Tumor development and tumor burden was also affected in 
Trim27   /   mice. Such mice displayed intermediate expressivity of 
tumor resistance, with tumor incidence and burden statistically 
signiﬁ cantly lower than observed in Trim27   /+ mice (number 
of tumors per mouse: Trim27   /   vs Trim27   /+ , mean = 5.46, 95% 
CI = 3.28 to 7.64 vs mean = 9.76, 95% CI = 6.75 to 12.77,  P < .05, 
  2 test), but higher than observed in Trim27   /   mice (number of 
tumors per mouse: Trim27   /   vs Trim27   /+ , mean = 2.46, 95% 
CI = 0.85 to 4.07 vs mean = 9.76, 95% CI = 6.75 to 12.77,  P < .001, 
  2 test) at week 20 ( Supplementary  Figure  4 ,  A – C , available 
online). Together , these results document that Trim27 transcript 
abundance critically inﬂ uences tumor incidence as well as tumor 
expansion in the system studied. 
 To explore the distribution of Trim27 gene activation, histo-
chemical detection was done for LacZ activity resulting from the 
  -Geo insertion that disrupted the Trim27 locus in Trim27   /   
mice, which provides a reporter for locus activity ( 9 ). To obtain an 
initial overview , we performed full mount in situ staining using 
ﬁ xed whole tumors or skin. This revealed considerable   -Geo re-
porter activity in tumors from mice carrying the trapped allele but 
not in tumors from Trim27   /+ mice ( Supplementary  Figure  4 ,  E , 
available online). Staining was widespread across the tumor tissue 
with some variegation present in both early (week 14) and late 
cancers (week 20). Higher activity, relative to that at week 20 , was 
generally observed at week 14. These observations are in line with 
results from qRT- PCR- based analysis indicating that more sub-
stantive Trim27 expression was present in early cancers ( Figure 1, 
D and E ). Histochemical detection using frozen sectioned material 
conﬁ rmed widespread   -Geo reactivity in tumor tissue but not in 
tumor-adjacent skin ( Supplementary  Figure  4 ,  F , available 
online). Tumors showed speciﬁ c staining in the epithelial layer of 
the lesions mostly involving the upper (squamous) layer of the 
epidermis ( Supplementary  Figure  4 ,  G and  H , available online) 
from which these cancers are thought to originate ( 21 , 30 ). 
Together , these results strongly support a view whereby ectopic 
activation of the Trim27 locus is localized to cancer tissue consis-
tent with a tumor autonomous role of TRIM27. 
 Senescence  Propensity  in  Embryo  Fibroblasts  With 
 Trim27  Disruption 
 To investigate the mechanism by which Trim27 loss may prevent 
tumor development , we used MEFs isolated from 13.5- day- old 
mouse embryos, a cell type frequently used to study the mechanism 
of immortalization and oncogenic transformation ex vivo ( 31 ). 
Initially, we evaluated early passage 3 (P3) MEFs from Trim27   /+ 
and Trim27   /   littermates under standard growth conditions. We 
found no difference in either proliferation capacity (live cell 
numbers on days 1 through 7 for Trim27   /+ and Trim27   /   P3 
MEFs were similar) ( Figure 4, A ) or the phenotypic appearance of 
these cells ( Supplementary  Figure  5 ,  C , available online), suggest-
ing that disruption of the Trim27 gene does not affect viability or 
proliferative capacity in early passaged MEFs. Explanted primary 
rodent fibroblasts have a finite life span in culture resulting 
in cessation of cell proliferation after a limited number of cell 
divisions ( 23 , 32 – 34 ). Cessation of population growth (crisis) is 
eventually overcome through outgrowth of rare variant cells with 
stochastically acquired mutations that serve to immortalize such 
primary cells in vitro. 
 To test whether Trim27 loss may affect the immortalization 
propensity of primary ﬁ broblasts, we assessed the long-term 
proliferative capacity and life span of the various MEF lines using 
serial passage as prescribed by the 3T3 protocol ( 23 ). After a 
period of active growth (approximately 7 – 8 passages), the prolifer-
ative index of both Trim27   /+ and Trim27   /   MEFs declined 
( Figure 4, B ) alongside increased cell hypertrophy ( Figure 4, C ), 
an indicator of cellular senescence ( 35 , 36 ). However, although 
Trim27   /+ MEFs escaped from this cessation of growth after about 
20 days (7 – 10 passages), resuming and eventually adopting a stable 
rate of proliferation as typical for immortalized cultures, Trim27   /   
MEFs underwent extended growth cessation with near absent 
proliferative activity for more than 50 days  (approximately  20 
passages) ( Figure 4, B ). This differential behavior of Trim27   /+ 
and Trim27   /   MEFs was reproducibly seen in further litter-
mate-paired MEF lines derived from independent litters (n = 3) 
( Supplementary  Figure  5 ,  A  and  B , available online). During the 
extended time of growth arrest observed for cultures of Trim27   /   
MEFs, replicative senescence was indicated by an absence of 
mitotic activity, increase in the number of cells with hypertrophic 
morphology and positivity for the senescence  marker enzyme 
SA-  -gal (percentage of SA-  -gal-positive cells: Trim27   /+ MEFs 
vs Trim27   /   MEFs, mean = 14.2%, 95% CI = 11.1% to 17.4% vs 
mean = 53.3%, 95% CI = 48.7% to 57.9% at passage 17,  P < .001) 
( 24 ) ( Figure 4, C and D ,  Supplementary  Figure  5 ,  D , available 
online). We concluded that loss of Trim27 decreased the incidence 
of spontaneous immortalization by increasing the propensity of 
primary mouse cells in culture to undergo senescence. 
 Effect of  Trim27 Disruption  on  HRAS V12-Induced 
 Senescence 
 Culture- associated replicative senescence in vitro is  fueled by 
tissue culture inherent stresses including substratum stiffness and 
high oxygen pressure ( 37 ) and may have limited relevance in an 
organismal context. However, oncogenes including oncogenic 
versions of the RAS proto-oncogene family elicit senescence in 
cells and RAS oncogene – driven senescence is an established phys-
iologically relevant mechanism of tumor suppression that limits 
transformation by oncogenic RAS mutants ( 35 , 38 – 43 ). Mutational 
activation of RAS is a prevalent oncogenic initiator event in chem-
ically induced skin cancers in  mice ( 27 , 44 ). Because Trim27 loss 
exaggerates replicative senescence, we investigated whether it also 
exaggerates senescence driven by RAS-activation. We introduced 
an activated RAS allele (HRAS V12) into Trim27   /+ and Trim27   / 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MEFs using retroviral transduction. Consistent with previous 
observations ( 38 ), expression of HRAS V12 (Ras) in Trim27   /+ MEFs 
resulted in senescence expressivity ( Figure 5 ). However, and as 
seen with replicative senescence ( Figure 4 ), the propensity for this 
response was considerably greater in Trim27   /   MEFs than in 
Trim27   /+ MEFs, as indicated by increased attenuation of prolifer-
ation activity ( Figure 5, A ), enhanced appearance of cell hypertro-
phy , and an increase in the percentage of SA-  -gal positivity 
present in such cultures about 10 days following Ras transduction 
(percentage of SA-  -gal-positive cells: Trim27   /+ MEFs  +  Ras vs 
Trim27   /   MEFs  +  Ras, mean = 24.0%, 95% CI = 19.9% to 28.1% 
vs mean = 37.3%, 95% CI = 32.2% to 42.4%,  P < .05) ( Figure 5, B ). 
Similar results were obtained using paired Trim27   /+ and Trim27   /   
 
A
C
Li
ve
 c
el
l n
um
be
rs
(x1
04 )
Days
0
10
20
30
1 2 3 5 6 7
Trim27 -/-
Trim27 + /+
B
Pr
ol
ife
ra
tio
n 
In
de
x
Passages
0
1
2
3
4
5
6
4 6 8 10 12 14 16 18 20 22 24 26 28
Trim27 -/-
Trim27 + /+
Cell volume (P5) Cell volume (P16)
Ev
en
ts
0
0.5
1
1.5
2
11
.
1
17
.7
21
.4
24
.1
26
.3
28
.1
29
.8
31
.3
32
.7
33
.9
35
.1
Trim27 + /+
Trim27 -/-
0
0.5
1
1.5
2
11
.1
17
.7
21
.4
24
.1
26
.3
28
.1
29
.8
31
.3
32
.7
33
.9
35
.1
Trim27 + /+
Trim27 -/-
D
P3P3 P17 P17
Passages
0
20
40
60
***
Trim27 + /-
Trim27 + /+
 
 Figure 4 .  Growth properties of Trim27   /   mouse embryonic ﬁ broblasts 
(MEFs) compared with litter-matched TRIM27   /   control MEFs.  A ) Growth 
of early-passage (passage 3) MEFs over 7 days was determined by 
counting the number of viable cells in a  six -well plate by trypan blue 
exclusion. Results from one representative experiment are shown. 
Similar results were obtained when the experiment was repeated with 
three independent MEF preparations.  B ) The immortalization propen-
sity in MEFs with Trim27 disruption. MEFs with indicated genotypes 
were seeded and passaged using the 3T3 protocol. The cumulative 
proliferation index calculated from the ratio between the number of 
cells plated and the number of cells harvested before further subculture 
is shown. Data points represent the mean count of cells harvested 
from three replicate dishes. The data are representative for three inde-
pendent cell preparations ( Supplementary  Figure  5 , available online). 
 C ) Cell volume in early - and late-passage  MEF s was measured by a 
Scepter automated cell counter. Data are representative for three inde-
pendent MEF preparations.  D ) The percentage of senescence-associated 
  -galactosidase (SA-  -gal ) – positive cells was determined by counting 
SA-  -gal-positive cells in four eye ﬁ elds each in three parallel dishes. 
Mean expression levels and 95% conﬁ dence intervals ( error bars ) of a 
representative experiment are shown. *** P < .001 using heteroscedas-
tic two-tailed Student’s  t test. 
  
 Figure 5 .  Trim27 loss exacerbates HRAS V12 oncogene-induced senes-
cence. Passage 3 Trim27   /   and Trim27   /   mouse embryonic ﬁ broblasts 
(MEFs) were infected with retrovirus encoding oncogenic HRAS V12 (Ras) 
or control (empty) vector and selected with puromycin.  A ) Growth 
curves depict the number of viable cells counted at the indicated times 
after infection and selection. The means and corresponding 95% conﬁ -
dence intervals ( error bars ) of three replicates within a representative 
experiment are shown. Three independent experiments were performed 
with similar results.  B ) The percentage of  senescence-associated 
  -galactosidase (SA-  -gal ) – positive Trim27   /   and Trim27   /   MEFs  were 
 calculated after retroviral infections. Mean expression levels and 95% 
conﬁ dence intervals ( error bars ) of a representative experiment were 
derived by counting SA-  -gal-positive cells in  three  eye ﬁ elds each in 
three parallel dishes. * P < .05 using heteroscedastic two-tailed Student’s 
 t test.  C and  D ) HRAS V12 oncogene expression and senescence signaling 
 were  assessed by immunoblot analysis of MEF cell lysates collected at 
day 7 after retroviral infection and selection by probing for Pan Ras, Arf 
(p19), p21CIP1/KIP1 (p21), and TP53 (p53). Detection of   -actin was used 
as a loading control. Data from two independent experiments are shown, 
involving HRAS V12 expressed from either the pBabe-Puro (-Puro)  ( C ) 
or MSCV IRES GFP (-GFP) retroviral backbone  ( C and  D ) (Addgene). 
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MEF preparations from three different litters (not shown). The 
enhanced response of Trim27   /   cells was not because of exagger-
ated expression of the HRAS V12 protein in these cells nor the 
enhanced accumulation of the senescence drivers p19-ARF (p19), 
p21CIP1/KIP1 (p21), and TP53 (p53) ( Figure 5, C and D ), known 
to arise as a direct consequence of oncogenic HRAS V12 activation 
( 22 , 35 , 45 , 46 ). This indicated that HRAS V12  signaling, including 
the induction of senescence-associated proteins, occurs normally 
in Trim27   /   cells. Hence, Trim27 loss exaggerates loss of prolif-
erative capacity and cellular senescence in response to oncogenic 
stress. 
 To assess if senescence arises in Trim27   /   cancers in vivo and 
if senescence propensity in such cancers is enhanced in comparison 
to cancers arising in Trim27   /+ backgrounds, we probed sections of 
mouse tumors for the presence of SA-  -gal activity (n = 3). This 
analysis revealed striking evidence for widespread senescence in 
Trim27   /   cancers that did not , however , extend to cancer adja-
cent skin nor was it seen in cancers with Trim27   /+ background 
( Supplementary  Figure  6 , available online). These results are 
consistent with a view whereby enhanced senescence propensity is 
a feature arising in Trim27   /   backgrounds in conjunction with 
oncogenic transformation, further explaining the reduced disease 
incidence and progression seen in the Trim27   /   background. 
 Effect of  Trim27  Loss on Senescence and Tumor 
Propensity  in  a Cancer  Model  With  Rb1  Loss 
 A number of studies demonstrate the importance of the RB1 family 
proteins in executing the cellular senescence response ( 35 , 39 , 47 , 48 ). 
Moreover, we previously reported that TRIM27 overexpression 
attenuates  RB1- driven senescence expressivity in human cells ( 19 ). 
To examine whether RB1 signaling plays a role in the increased 
senescence propensity seen in Trim27   /   MEFs, we infected early 
passage Trim27   /   and Trim27   /+ MEFs from littermate embryos 
with either retrovirus encoding the human papillomavirus 16 E7 
protein, which binds and inactivates RB family proteins, or a con-
trol (empty) virus. Following selection for virus uptake , we exam-
ined the proliferation behavior of such cultures using serial passage 
as scheduled by the 3T3 protocol ( Figure 6, A ). E7 expression 
effectively inhibited crisis and rescued proliferation in Trim27   /   
cells, yielding proliferation capacity that was indistinguishable 
between Trim27   /+ and Trim27   /   cells, hence providing evidence 
that RB1 family protein activity is required for the extended 
growth cessation in  Trim27- deficient primary MEFs. 
 To further substantiate this view , we paired mice with an engi-
neered defect in the mouse retinoblastoma protein – encoding locus 
(Rb1) ( 25 ) with mice carrying the Trim27 disruption. Whereas 
Trim27   /   MEFs with wild-type Rb1 expression developed 
extended proliferation inactivity, as previously observed, Trim27   /   
MEFs with homozygous Rb1 defect adopted stable proliferation 
without signs of crisis or senescence, corroborating the notion that 
Rb1 function is critically required to establish the exaggerated 
senescence response seen in Trim27   /   MEFs ( Figure 6, B ). 
 Considering these observations , we asked whether Trim27 
disruption affected cancer susceptibility in mice with hemizygous 
Rb1 loss (Rb   /   ). Such mice spontaneously develop pituitary and 
thyroid cancers with high penetrance through mechanisms of loss 
of heterozygosity ( 25 ). In contrast to mice with chemically induced 
skin cancers, where Trim27 disruption provides statistically signif-
icant cancer protection ( Figure 3 ), Trim27   /   (n = 29) and 
Trim27   /+ mice (n = 26) with hemizygous Rb1 loss showed 
identical cancer susceptibility, with similar time of onset, tumor 
frequency, and tumor spectrum (Trim27   /   Rb   /   mice vs 
Trim27   /+ Rb   /   mice: median survival = 14.0 vs 13.0 months; 
difference = 1.0 month, 95% CI = 0.5 to 1.6 months,  P = .14) 
( Figure 6, C and D ). This is consistent with the hypothesis that 
cancer protection by Trim27 loss requires intact Rb signaling. 
  
 Figure 6 .  Senescence and tumor propensity in models with Rb1 loss.  A ) 
Senescence development in Trim27   /   backgrounds following papillo-
mavirus E7 oncoprotein expression. Passage 3 mouse embryonic ﬁ bro-
blasts (MEFs) were infected with pBabe-puro-E7 or empty vector 
(Addgene) and selected with puromycin. Cells were cultured according 
to the 3T3 protocol. The data are representative for three independent 
cell preparations.  B ) Effect of Rb1 gene disruption on senescence 
arising in Trim27   /   backgrounds. MEFs with indicated genotypes were 
propagated in culture by following the 3T3 protocol. MEFs were derived 
from littermate embryos, generated by mating Trim27   /   Rb   /   mice. 
Accumulated numbers of proliferation index were calculated as 
described before. Representative data of three independent MEF prep-
arations are shown.  C ) Effect of Trim27 disruption on tumor suscepti-
bility and survival in Rb1-deﬁ cient genetic background. Kaplan – Meier 
survival curves showing time  to  death in Rb   /   Trim27   /   (n = 29), 
Rb   /   Trim27   /   (n = 26), Rb   /   Trim27   /   (n = 21) , and Rb   /   Trim27   /   (n = 
16). A two-sided  log -rank test was used to determine if Trim27 disrup-
tion affected survival in Rb   /   Trim27   /   vs Rb   /   Trim27   /   backgrounds. 
 D ) Tumor spectrum in mice with Trim27 disruption in Rb1-deﬁ cient 
genetic background was investigated , and the percentage of mice pre-
senting with pituitary tumors and/or thyroid tumors was determined. 
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 Discussion 
 We demonstrate here that TRIM27 expression is a contributing 
factor in the development of chemically induced skin cancer in 
mice. Previous publications have shown enhanced, and possibly 
aberrant, expression of TRIM27 transcript and protein in specific 
types of human cancer, including endometrial ( 6 ) and invasive 
breast cancer ( 7 ). Our data show that TRIM27 expression is also 
associated with cancers of the lung, colon, uterus, and prostate. 
Hence , TRIM27 overexpression may arise in an extended spectrum 
of sporadic human cancers. Our work provides strong evidence 
that TRIM27 overexpression has a putative role in these cancers 
by documenting that TRIM27 expression is a transformation 
promoting and hence a  cancer- driving event. 
 We show that TRIM27 loss leads to exaggerated senescence in 
response to replicative as well as oncogene-associated stress. 
Senescence is recognized for its role in limiting oncogenic trans-
formation , and hence exaggeration of this response in all likeli-
hood explains the reduced tumor incidence in mice with 
compromised TRIM27 expression. A link between TRIM27 and 
senescence is suggested by our earlier work documenting reduced 
RB  protein – driven senescence in human cells after enforced 
TRIM27 overexpression ( 19 ). The work shown here extends these 
observations and documents that RB1 signaling is a critical com-
ponent of the exacerbated senescence response seen in Trim27-
ablated mice. 
 Recent work has shown that TRIM27 overexpression confers 
resistance to oxidative stress, by decreasing the expression of 
thioredoxin binding protein-2 ( 26 ). Oxidative stress is thought to 
play a role in driving replicative as well as oncogene-associated 
senescence leading to p53 activation and the activation of stress 
activated kinases, culminating in enhanced p21CIP1/WAF1 
expression ( 49 , 50 ). However, we have found no evidence for 
enhanced p53 activation or p21 expression in Trim27   /   MEFs nor 
did we observe enhanced expression of murine thioredoxin binding 
protein-2 in skin, tumors , or MEFs from Trim27   /   mice (data not 
shown), suggesting that our observations may be unrelated to the 
transcriptional regulation of this gene and the resultant enhanced 
oxidative stress. 
 To generate mice with impaired TRIM27 expression , we used 
murine embryonic stem cells in which the TRIM27 locus was 
modiﬁ ed through insertion of a gene trap that leads to greater than 
80% reduction in TRIM27 transcript expression in all tissues 
tested. Apart from considerable cancer resistance, mice with 
trapped TRIM27 locus are normal without any evident deﬁ -
ciencies, suggesting that substantial loss of TRIM27 gene function 
is possible without overt toxic effects. The demonstrated reduction 
of cancer incidence and progression in mice with TRIM27 loss, 
and the documentation of enhanced TRIM27 expression in a wide 
spectrum of human cancers, indicates that TRIM27 inhibition is 
a potential pharmacological target for therapy and/or chemopre-
vention of cancer. 
 The presented study has several limitations, one being that a 
murine skin cancer model driven by carcinogen exposure is used 
rather than a genetically deﬁ ned model of a human cancer type 
where TRIM27 is found to be overexpressed. This currently limits 
the ability to predict whether cancer reduction extends to these 
human cancers. The study design investigating the effect of 
TRIM27 loss in chemically induced skin cancer was led by experi-
mental observations showing TRIM27 expression to be enhanced in 
these murine cancers, suggesting that this cancer type is a relevant 
model for studying the role of the expression change. While the 
 cancer- initiating driver alteration (K- or H-Ras), the cell of origin, 
and the genetics and biology of progression  have  been character-
ized in detail in the model used ( 21 ), chemically induced cancers 
do not rely on engineered and preexisting genetic alterations. In 
this , they may more closely resemble the natural evolution of 
sporadically emerging human cancers than do models reliant on 
speciﬁ c genetic changes. However, because the genetics of chemi-
cally induced cancers is likely to be heterogeneous , the current 
work does not allow prediction if TRIM27 overexpression gener-
ally limits cancer development or does so only in the context of 
speciﬁ c cancer-driving genetic event. Justiﬁ ed by the results 
reported here, it will be important in future work to test for mod-
iﬁ cation of cancer susceptibility in murine models of human cancers 
that show TRIM27 locus activation and in the context of geneti-
cally deﬁ ned murine models of cancer development. 
 A further limitation is that currently no data are available as to 
the spatial distribution of TRIM27 expression in human or murine 
cancer tissue. To provide a preliminary view , we monitored 
TRIM27 locus activation through histochemical detection of the 
  -Geo reporter gene that has been inserted and is transcribed in 
place of the TRIM27 encoding sequence in the Trim27-trapped 
mouse model. To conﬁ rm and extend these results , it will be 
important in future work to develop antibodies suitable for histo-
chemical detection of the TRIM27 protein in murine and human 
cancer tissue. 
 An important question that currently remains unanswered is 
whether TRIM27 loss is required in late cancer or merely plays a 
role in early cancers and during cancer initiation. Although our 
ﬁ ndings document the requirement for TRIM27 expression 
during tumor development, further investigations as to the need 
for TRIM27 during cancer progression are clearly warranted. 
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